Estimate of Phase IIIb completion date unchanged s Good Afternoon Dr. Hwang, Current patient enrollment statistics for all of our trials are proprietary. However, with respect to NCT01200992 we continue to estimate a study completion date of December 2013. The reasons for withdrawal of the sites are proprietary as well. However, I believe, in general, it is not uncommon for centers to enter and subsequently withdraw from participation in a study. And that part of our planning for recruitment for any study accounts for this dynamic. Best,Jonathan Jonathan NeelyDirector Investor RelationsEndo Pharmaceuticals, Inc.Phone: 610-459-6645Email: neely.jonathan@endo.com